ZBIO

Insider Trades

Name	Value	Action	Price	Current Price
Moulder Leon O JrDirector, Officer: Chief Executive Officer $1.0M60k shares BuyMay 18, 2026 $16.88 --
Moulder Leon O JrDirector, Officer: Chief Executive Officer $617k35k shares BuyApr 29, 2026 $17.62 --
Moulder Leon O JrDirector, Officer: Chief Executive Officer $451k25k shares BuyApr 28, 2026 $18.02 --
Fairmount Funds Management LLCDirector $3.0M150k shares BuyMar 31, 2026 $20.00 --
Lu HongboDirector $1.5M75k shares BuyMar 31, 2026 $20.00 --
Moulder Leon O JrDirector, Officer: Chief Executive Officer $657k34k shares BuyMar 31, 2026 $19.31 --

News

globenewswire.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 17

globenewswire.comZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summitglobenewswire.comJun 11

globenewswire.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicineglobenewswire.comJun 2

globenewswire.comZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RDglobenewswire.comMay 28

Trade ZBIO

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

CEO: Leon Oliver Moulder Jr.
IPO Date: Sep 13, 2024

Market Data

Open: $18.93
High: $19.88
Low: $18.72
Volume: 2.1M
Avg Volume: 708.2K
52W High: $44.60
52W Low: $8.91

Valuation

Market Cap: $883M
Enterprise Value: $735M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-172M
Revenue: $10M
Net Income: $-378M
Cash: $111M
Debt: $80M

Events

EarningsAug 11

EPS est. -0.89